Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy. Report of the second neonatal meningitis cooperative study group

G. H. McCracken, S. G. Mize, N. Threlkeld

Research output: Contribution to journalArticle

Abstract

In a multicentre controlled trialin the U.S.A. and Latin America 52 infants with meningitis and ventriculitis were randomly assigned to receive either systemic ampicillin and gentamicin or intraventricular gentamicin plus systemic antimicrobial agents. The aetiological agents most often encountered were Escherichia coli in the U.S. infants and Salmonella spp. in Latin American infants. Infants receiving systemic antibiotics plus intraventricular gentamicin had a significantly higher mortality rate (42.9%) than those who received systemic therapy only (12.5%). Duration of positive CSF cultures and morbidity rates were not significantly different in the two treatment groups. The concentrations of gentamicin in ventricular and lumbar CSF 1-6 h after an intraventricular dose of 2.5 mg gentamicin were 10-130 μg/ml and 8-85 μg/ml, respectively. The study was terminated early because of the higher mortality rate in the intraventricular-therapy group. Intraventricular gentamicin should not be used as routine treatment for neonatal meningitis caused by gram-negative enteric bacilli.

Original languageEnglish (US)
Pages (from-to)787-791
Number of pages5
JournalLancet
Volume1
Issue number8172
StatePublished - 1980

Fingerprint

Gentamicins
Meningitis
Therapeutics
Macrophage Colony-Stimulating Factor
Latin America
Mortality
Ampicillin
Group Psychotherapy
Anti-Infective Agents
Salmonella
Bacillus
Escherichia coli
Anti-Bacterial Agents
Morbidity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy. Report of the second neonatal meningitis cooperative study group. / McCracken, G. H.; Mize, S. G.; Threlkeld, N.

In: Lancet, Vol. 1, No. 8172, 1980, p. 787-791.

Research output: Contribution to journalArticle

@article{ce71e1be05a6411c9f6c58683d6eb939,
title = "Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy. Report of the second neonatal meningitis cooperative study group",
abstract = "In a multicentre controlled trialin the U.S.A. and Latin America 52 infants with meningitis and ventriculitis were randomly assigned to receive either systemic ampicillin and gentamicin or intraventricular gentamicin plus systemic antimicrobial agents. The aetiological agents most often encountered were Escherichia coli in the U.S. infants and Salmonella spp. in Latin American infants. Infants receiving systemic antibiotics plus intraventricular gentamicin had a significantly higher mortality rate (42.9{\%}) than those who received systemic therapy only (12.5{\%}). Duration of positive CSF cultures and morbidity rates were not significantly different in the two treatment groups. The concentrations of gentamicin in ventricular and lumbar CSF 1-6 h after an intraventricular dose of 2.5 mg gentamicin were 10-130 μg/ml and 8-85 μg/ml, respectively. The study was terminated early because of the higher mortality rate in the intraventricular-therapy group. Intraventricular gentamicin should not be used as routine treatment for neonatal meningitis caused by gram-negative enteric bacilli.",
author = "McCracken, {G. H.} and Mize, {S. G.} and N. Threlkeld",
year = "1980",
language = "English (US)",
volume = "1",
pages = "787--791",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8172",

}

TY - JOUR

T1 - Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy. Report of the second neonatal meningitis cooperative study group

AU - McCracken, G. H.

AU - Mize, S. G.

AU - Threlkeld, N.

PY - 1980

Y1 - 1980

N2 - In a multicentre controlled trialin the U.S.A. and Latin America 52 infants with meningitis and ventriculitis were randomly assigned to receive either systemic ampicillin and gentamicin or intraventricular gentamicin plus systemic antimicrobial agents. The aetiological agents most often encountered were Escherichia coli in the U.S. infants and Salmonella spp. in Latin American infants. Infants receiving systemic antibiotics plus intraventricular gentamicin had a significantly higher mortality rate (42.9%) than those who received systemic therapy only (12.5%). Duration of positive CSF cultures and morbidity rates were not significantly different in the two treatment groups. The concentrations of gentamicin in ventricular and lumbar CSF 1-6 h after an intraventricular dose of 2.5 mg gentamicin were 10-130 μg/ml and 8-85 μg/ml, respectively. The study was terminated early because of the higher mortality rate in the intraventricular-therapy group. Intraventricular gentamicin should not be used as routine treatment for neonatal meningitis caused by gram-negative enteric bacilli.

AB - In a multicentre controlled trialin the U.S.A. and Latin America 52 infants with meningitis and ventriculitis were randomly assigned to receive either systemic ampicillin and gentamicin or intraventricular gentamicin plus systemic antimicrobial agents. The aetiological agents most often encountered were Escherichia coli in the U.S. infants and Salmonella spp. in Latin American infants. Infants receiving systemic antibiotics plus intraventricular gentamicin had a significantly higher mortality rate (42.9%) than those who received systemic therapy only (12.5%). Duration of positive CSF cultures and morbidity rates were not significantly different in the two treatment groups. The concentrations of gentamicin in ventricular and lumbar CSF 1-6 h after an intraventricular dose of 2.5 mg gentamicin were 10-130 μg/ml and 8-85 μg/ml, respectively. The study was terminated early because of the higher mortality rate in the intraventricular-therapy group. Intraventricular gentamicin should not be used as routine treatment for neonatal meningitis caused by gram-negative enteric bacilli.

UR - http://www.scopus.com/inward/record.url?scp=0018839963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018839963&partnerID=8YFLogxK

M3 - Article

C2 - 6102677

VL - 1

SP - 787

EP - 791

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8172

ER -